Shares of Glenmark Life Sciences fell by over 2% to ₹858.20 following a drop in the company’s first-quarter results for fiscal 2025. The company reported a 17.69% decrease in standalone net profit, which fell to ₹111.48 crore from ₹135.45 crore in the same quarter last year.
Revenue from operations increased slightly by 1.75% year-on-year to ₹588.62 crore. However, profit before tax (PBT) declined by 17.45% to ₹150.24 crore compared to ₹182 crore in the previous year. EBITDA also saw a decrease of 15.38%, coming in at ₹165 crore, down from ₹195 crore in the same quarter last year. The EBITDA margin decreased to 28% from 33.7%.
As of 1:27 PM, the shares were trading 2.73% lower at ₹852.30 on the NSE.
TOPICS:
Glenmark Life Sciences